GENELINK FEATURED IN MID-WEEK COMMENT EDITORIAL
December 11, 2002

MARGATE, NJ - (Business Wire) - Dec. 11, 2002 -- GeneLink BioSciences, Inc. (OTC BB:GNLK- News) is featured in Larry Oakley's Mid-Week Comment editorial at www.WallStreetCorner.com. 

Oakley pointed out that GNLK has developed three different marketing channels: (1) Direct to consumers through a license to its first direct to consumer company; (2) Over the counter sales through licenses to companies that sell their products through retail stores; & (3) Sales to licensees that sell cosmetic & nutritional products to physicians. 

Commenting on the first significant quarterly revenue, Oakley said: "The Q3 revenue constituted initial orders from distributors in these three channels. As one example, one of the over the counter licensees sells a skin cream. The customer who buys the cream will get a DNA collection kit with simple instructions plus a convenient way to send the easily collected sample to GNLK's facility for analysis. The results are sent by GNLK to the licensee & are used to prepare an individual formulation of skin cream specifically for that customer. 

"As sales of GNLK's DNA Collection Kits, plus GNLK's subsequent analysis service are made to licensees that expand their reach nationally, this special situation will, in my opinion, be generating very attractive profits. A good portion of those profits will be in the form of royalty income on the analysis service. I particularly like royalty income, because almost 100% of it jumps right to the bottom line. 

"I strongly suggest you look into this situation. It's one of the few I've found that has really outstanding long-term appreciation potential, & it's now at the beginning of its growth period." 

About WallStreetCorner: www.WallStreetCorner.com was formed three years ago as a venue for Larry Oakley's Conservative Speculator newsletter, published since 1987. It and its three associated editorial columns at WallStreetCorner are now regularly read by investors and financial professionals in 61 countries. 

About GeneLink: www.genelink.info. GeneLink BioSciences, Inc., a pioneer DNA banking and hereditary genetic information service has developed a proprietary method for genetic assessments (patents pending) and has begun to license these breakthrough nutragenetic and dermagenetic profiles to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement and health care industries. 

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE:GeneLink BioSciences, Inc.